FLINT, Mich. – Dec. 7, 2016 – The nation’s largest independent specialty pharmacy unifies its family of infusion companies to operate under one name.

Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty Infusion Group, a new brand uniting five subsidiaries—American Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites.

To learn more about Diplomat’s specialty infusion services, visit diplomat.is/specialty-infusion.

“As we continue to build on the work we have done, we are excited to move forward with the launch of our new Diplomat Specialty Infusion Group brand,” said Diplomat CEO and Chairman Phil Hagerman. “Together, our combined resources allow us to continue to build upon our expertise and services for patients with specialized needs.”

Diplomat Specialty Infusion Group companies will continue their focused services within their key areas of excellence, including:

  • Hemophilia and other bleeding disorders
    • High-touch management for populations with rare bleeding disorders and patients with hemophilia A, hemophilia B, inhibitors, or von Willebrand disease.
  • Hereditary angioedema (HAE)
    • Specialized programs that guide HAE patients through their medical journey.
  • Alpha-1 antitrypsin deficiency
    • Home infusion services specifically designed for patients with alpha-1 antitrypsin deficiency.
  • Immune globulin
    • Home delivery and administration of immune globulin therapies, including innovative patient and physician support programs.
  • Parenteral and enteral nutrition
    • Customized treatments and infusion support

“This brand opens a new door for us,” said Phil Rielly, Diplomat vice president and president of Diplomat Specialty Infusion Group. “Our patients are our driving force. They are our motivation to continue pushing for better therapies and educating on the industry. We are determined to keep working and advocating under the new brand on their behalf—to be the voice our patients don’t always have.”

To learn more about Diplomat, visit diplomat.is.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise. 

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is.

###

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

John Louis, Director, Category Management,
Specialty Infusion Group
610.924.5128 | jlouis@diplomat.is

Twitter